Related Experiment Video
Updated: Aug 5, 2026
06:10
Non-Viral Engineering of Primary Human T Cells via Homology-Mediated End-Joining Targeted Integration of Large DNA Templates
Published on: May 9, 2025
Engineering CAR-T cells for solid tumors: Overcoming the microenvironment through integrated design and clinical
Samuel Obiosa Onyekweli1, Gloria Osayamen Omoruyi1, Christopher Oloruntoba Akintayo1
1Department of Internal Medicine, Obafemi Awolowo University Teaching Hospital Complex, Ile-Ife, Nigeria.
Oncoscience
|August 1, 2026
Summary
Chimeric antigen receptor T-cell (CAR-T) therapy shows promise for solid tumors. Recent breakthroughs in engineering CAR-T cells for resilience and targeting specific antigens are improving response rates in challenging cancers.
Area of Science:
- Immunology
- Oncology
- Biotechnology
Background:
- Chimeric antigen receptor T-cell (CAR-T) therapy has revolutionized blood cancer treatment but faces significant challenges in solid tumors, with response rates around 9%.
- Key obstacles include tumor antigen heterogeneity, physical barriers within dense tumor stroma, and immunosuppressive microenvironments that induce T-cell exhaustion via epigenetic reprogramming.
- Recent advancements in CAR-T cell engineering and delivery strategies are beginning to overcome these limitations.
Purpose of the Study:
- To review recent breakthroughs and emerging strategies in CAR-T therapy for solid tumors.
- To synthesize mechanistic insights, engineering approaches, and clinical evidence defining the current landscape of solid tumor CAR-T development.
- To propose a framework for next-generation CAR-T therapies targeting solid malignancies.
Main Methods:
- Review of recent clinical trials and preclinical research in CAR-T therapy for solid tumors.
- Analysis of novel engineering strategies focused on enhancing T-cell resilience and overcoming the tumor microenvironment.
- Synthesis of data on emerging platforms, including in vivo CAR-T generation and advanced targeting circuits.
Main Results:
- Intracerebroventricular GD2-targeting CAR-T cells achieved durable complete responses in diffuse midline gliomas.
- Satricabtagene autoleucel (CLDN18.2-targeting) demonstrated superiority in advanced gastric cancer.
- GPC3-targeting CAR-T cells armored with a dominant-negative TGF-β receptor showed significantly improved response rates (50-57%) in hepatocellular carcinoma.
Conclusions:
- Engineering CAR-T cells for resilience, through metabolic, epigenetic, and microenvironmental shielding strategies, is crucial for solid tumor efficacy.
- Emerging strategies like logic-gated targeting and in vivo generation hold significant potential for future CAR-T development.
- Further research is needed to address persistent limitations and optimize CAR-T therapy for broad application in solid tumors.
Related Concept Videos
01:27Tumor Immunotherapy
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
02:17The Tumor Microenvironment
Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...